<tbody><tr><th scope="col">No.</th>
			<th scope="col">Drug<br>
			Name</th>
			<th scope="col">Active Ingredient</th>
			<th scope="col" style="width: 100.2px;">Approval Date</th>
			<th scope="col" style="width: 907.79px;">FDA-approved use on approval date</th>
		</tr><tr><td>59.</td>
			<td><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761108">Ultomiris</a></span></span></span></span></span></span></span></span></td>
			<td>ravulizumab</td>
			<td style="width: 100.2px;">12/21/2018</td>
			<td>To treat paroxysmal nocturnal hemoglobinuria (PNH)<br>
			Press Release<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="a310112e-ec58-443d-ab44-16f0f3896ddb" href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-ultomiris" title="Drug Trials Snapshots: ULTOMIRIS">Drug Trials Snapshot</a></td>
		</tr><tr><td>58.</td>
			<td><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761116">Elzonris</a></span></span></span></span></span></span></span></span></td>
			<td>tagraxofusp-erzs</td>
			<td style="width: 100.2px;">12/21/2018</td>
			<td>To treat blastic plasmacytoid dendritic cell neoplasm (BPDCN)<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="37b9c1d7-2fcb-4dc8-b00d-2b5f7a1fdd00" href="/news-events/press-announcements/fda-approves-first-treatment-rare-blood-disease" title="FDA approves first treatment for rare blood disease">Press Release</a><br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="b2d15752-b23b-4e3b-b417-88b4a30edace" href="/drugs/drug-approvals-and-databases/drug-trial-snapshot-elzonris" title="Drug Trial Snapshot: ELZONRIS">Drug Trials Snapshot</a></td>
		</tr><tr><td>57.</td>
			<td><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761102">Asparlas</a></span></span></span></span></span></span></span></span></td>
			<td>calaspargase pegol-mknl</td>
			<td style="width: 100.2px;">12/20/2018</td>
			<td>To treat acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years<br><a href="Drug Trials Snapshots: ASPARLAS">Drug Trials Snapshot</a></td>
		</tr><tr><td>56.</td>
			<td><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210166">Motegrity</a></span></span></span></span></span></span></span></span></td>
			<td>prucalopride</td>
			<td style="width: 100.2px;">12/14/2018</td>
			<td>To treat chronic idiopathic constipation<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="bfc099e7-ae26-4858-9fbd-a5b7fa0d8495" href="/drugs/drug-trials-snapshots-motegrity" title="Drug Trials Snapshots: MOTEGRITY">Drug Trials Snapshot</a></td>
		</tr><tr><td>55.</td>
			<td><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=211349">Xospata</a></span></span></span></span></span></span></span></span></td>
			<td>gilteritinib</td>
			<td style="width: 100.2px;">11/28/2018</td>
			<td>To treat patients who have relapsed or refractory acute myeloid leukemia (AML)<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="3ace0bc1-aea1-47df-9ec8-beb3c5f29dcf" href="/news-events/press-announcements/fda-approves-treatment-adult-patients-who-have-relapsed-or-refractory-acute-myeloid-leukemia-aml" title="FDA approves treatment for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a certain genetic mutation">Press Release</a><br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="3c0734d4-fe98-4b75-a44c-bb1b21c72943" href="/drugs/resources-information-approved-drugs/drug-trial-snapshot-xospata" title="Drug Trial Snapshot: XOSPATA">Drug Trials Snapshot</a></td>
		</tr><tr><td>54.</td>
			<td><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=208078">Firdapse</a></span></span></span></span></span></span></span></span></td>
			<td>amifampridine</td>
			<td style="width: 100.2px;">11/28/2028</td>
			<td>To treat&nbsp; Lambert-Eaton myasthenic syndrome (LEMS) in adults<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="926eddb4-20df-4334-b920-fc774b55f221" href="/news-events/press-announcements/fda-approves-first-treatment-lambert-eaton-myasthenic-syndrome-rare-autoimmune-disorder" title="FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder">Press Release</a><br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="b78273c5-e72b-4835-99d5-ee290e4b0f15" href="/drugs/drug-trial-snapshot-firdapse" title="Drug Trial Snapshot: FIRDAPSE">Drug Trials Snapshot</a></td>
		</tr><tr><td>53.</td>
			<td><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210861">Vitrakvi</a></td>
			<td>larotrectinib</td>
			<td style="width: 100.2px;">11/26/2018</td>
			<td>To treat patients whose cancers have a specific genetic feature (biomarker)<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="79a68ea2-84f7-4420-9a24-11b336e0006d" href="/news-events/press-announcements/fda-approves-oncology-drug-targets-key-genetic-driver-cancer-rather-specific-type-tumor" title="FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor">Press Release</a><br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="8181e1d2-9cd1-4d4b-be34-ba2f66da9a6a" href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-vitrakvi" title="Drug Trials Snapshots: VITRAKVI">Drug Trials Snapshot</a></td>
		</tr><tr><td>52.</td>
			<td><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210656">Daurismo</a></span></span></span></span></span></span></span></span></td>
			<td>glasdegib</td>
			<td style="width: 100.2px;">11/21/2018</td>
			<td>To treat newly-diagnosed acute myeloid leukemia (AML) in adult patients<br>
			Press Release&nbsp;<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="b0269c1e-5703-4a5d-b943-8b0b55d8d715" href="/drugs/resources-information-approved-drugs/drug-trial-snapshot-daurismo" title="Drug Trial Snapshot: DAURISMO">Drug Trials Snapshot</a></td>
		</tr><tr><td>51.</td>
			<td><span><span><span><span><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761107">Gamifant</a></span></span></span></span></span></span></span></span></span></span></span></span></td>
			<td>emapalumab-lzsgemapalumab-lzsg</td>
			<td style="width: 100.2px;">11/20/2018</td>
			<td>To treat primary hemophagocytic lymphohistiocytosis (HLH)<br>
			Press Release<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="cd0c4e00-3225-488f-8a5e-13859ce0e01c" href="/drugs/drug-approvals-and-databases/drug-trial-snapshot-gamifant" title="Drug Trial Snapshot: GAMIFANT">Drug Trials Snapshot</a></td>
		</tr><tr><td>50.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210910">Aemcolo</a></span></span></span></span></td>
			<td>rifamycin</td>
			<td style="width: 100.2px;">11/16/2018</td>
			<td>To treat travelersâ€™ diarrhea<br>
			Press Release<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="03e0b3f4-1e22-4b94-a5db-9ef2e3b24fcc" href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-aemcolo" title="Drug Trials Snapshots: AEMCOLO">Drug Trials Snapshot</a></td>
		</tr><tr><td>49.</td>
			<td><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210598">Yupelri</a></span></span></span></span></span></span></span></span></td>
			<td>revefenacin</td>
			<td style="width: 100.2px;">11/9/2018</td>
			<td>To treat patients with chronic obstructive pulmonary disease (COPD)<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="60a369cd-b8b0-48c6-8127-a374b8196f25" href="/drugs/drug-trials-snapshots-yupelri" title="Drug Trials Snapshots: YUPELRI">Drug Trials Snapshot</a></td>
		</tr><tr><td>48.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210868">Lorbrena</a></span></span></span></span></td>
			<td>lorlatinib</td>
			<td style="width: 100.2px;">11/2/2018</td>
			<td>To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="262ae313-e52f-435f-89ab-dbb952d7296f" href="/drugs/drug-trials-snapshots-lorbrena" title="Drug Trials Snapshots: LORBRENA">Drug Trials Snapshot</a></td>
		</tr><tr><td>47.</td>
			<td><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210854">Xofluza</a></span></span></span></span></span></span></span></span></td>
			<td>baloxavir marboxil</td>
			<td style="width: 100.2px;">10/24/2018</td>
			<td style="width: 907.79px;">To treat&nbsp;acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours.<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="0f9511e1-5cac-477f-ac4b-5ff2475c2925" href="/news-events/press-announcements/fda-approves-new-drug-treat-influenza" title="FDA approves new drug to treat influenza ">Press Release</a><br>
			Drug Trials Snapshot</td>
		</tr><tr><td>46.</td>
			<td><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=211651" target="_blank">Talzenna</a></td>
			<td>talazoparib</td>
			<td style="width: 100.2px;">10/16/2018</td>
			<td style="width: 907.79px;">To treat&nbsp;locally advanced or metastatic breast cancer patients with a germline BRCA mutation.<br>
			Drug Trials Snapshot</td>
		</tr><tr><td>45.</td>
			<td><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=211172">Tegsedi</a></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></td>
			<td>inotersen</td>
			<td style="width: 100.2px;">10/5/2018</td>
			<td style="width: 907.79px;">To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults<br>
			Drug Trials Snapshot</td>
		</tr><tr><td>44.</td>
			<td><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761092">Revcovi</a></td>
			<td>elapegademase-lvlr</td>
			<td style="width: 100.2px;">10/5/2018</td>
			<td style="width: 907.79px;">To treat Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID)<br>
			Drug Trials Snapshot</td>
		</tr><tr><td>43.</td>
			<td><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=209816">Nuzyra</a></td>
			<td>omadacycline</td>
			<td style="width: 100.2px;">10/2/2018</td>
			<td style="width: 907.79px;">To treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="06bf59cd-9311-4bb5-8ad9-ce2455fa1726" href="/drugs/drug-trials-snapshots-nuzyra" title="Drug Trials Snapshots: NUZYRA">Drug Trials Snapshot for community-acquired bacterial pneumonia</a><br>
			Drug Trials Snapshot for bacterial skin infections</td>
		</tr><tr><td>42.</td>
			<td><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=209521">Seysara</a></td>
			<td>sarecycline</td>
			<td style="width: 100.2px;">10/1/2018</td>
			<td style="width: 907.79px;">To treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="eaf51de3-fee7-4624-a1cc-ea8e84e8c9bd" href="/drugs/drug-approvals-and-databases/drug-trials-snapshot-seysara" title="Drug Trials Snapshot: SEYSARA">Drug Trials Snapshot</a></td>
		</tr><tr><td>41.</td>
			<td><span><span><span><span><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761097">Libtayo</a></span></span></span></span></span></span></span></span></span></span></span></span></td>
			<td>cemiplimab-rwlc</td>
			<td style="width: 100.2px;">9/28/2018</td>
			<td style="width: 907.79px;">To treat cutaneous squamous cell carcinoma (CSCC)<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d4afd7ae-8704-4f6e-90b3-a59f33d171cd" href="/drugs/drug-approvals-and-databases/drug-trials-snapshot-libtayo" title="Drug Trials Snapshot: LIBTAYO">Drug Trial Snapshot</a></td>
		</tr><tr><td>40.</td>
			<td><span><span><span><span><a href="httphttp://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=211288">Vizimpro</a><a href="http://www.fda.gov/about-fda/website-policies/website-disclaimer" class="ext-disclaimer"><span class="fa fa-external-link" aria-hidden="true"></span><span class="sr-only">External Link Disclaimer</span></a></span></span></span></span></td>
			<td>dacomitinib</td>
			<td style="width: 100.2px;">9/27/2018</td>
			<td style="width: 907.79px;">To&nbsp;treat metastatic non-small-cell lung cancer<br>
			Drug Trials Snapshot</td>
		</tr><tr><td>39.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761063">Emgality</a></span></span></span></span></td>
			<td>galcanezumab-gnlm</td>
			<td style="width: 100.2px;">9/27/2018</td>
			<td style="width: 907.79px;">To&nbsp;treat metastatic non-small-cell lung cancer<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="4dfb8582-24ed-4bb7-b718-e647189f59ce" href="/drugs/drug-trials-snapshots-emgality" title="Drug Trials Snapshots: EMGALITY">Drug Trials Snapshot</a></td>
		</tr><tr><td>38.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=211155 ">Copiktra</a></span></span></span></span></td>
			<td>duvelisib</td>
			<td style="width: 100.2px;">9/24/2018</td>
			<td style="width: 907.79px;">To treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="f909dd30-1490-4615-8d68-4c682d3fb39c" href="/drugs/drug-trials-snapshots-copiktra" title="Drug Trials Snapshots: COPIKTRA">Drug Trials Snapshot</a></td>
		</tr><tr><td>37.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761089 ">Ajovy</a></span></span></span></span></td>
			<td>fremanezumab-vfrm</td>
			<td style="width: 100.2px;">9/14/2018</td>
			<td style="width: 907.79px;">For the preventive treatment of migraine in adults<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="f2178c78-dd3f-440d-b250-e29864eacb89" href="/drugs/drug-trials-snapshot-ajovy" title="Drug Trials Snapshot: AJOVY">Drug Trials Snapshot</a></td>
		</tr><tr><td>36.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761104">Lumoxiti</a></span></span></span></span></td>
			<td>moxetumomab pasudotox-tdfk</td>
			<td style="width: 100.2px;">9/13/2018</td>
			<td style="width: 907.79px;">To treat hairy cell leukemia<br><a href="/news-events/press-announcements/fda-approves-new-kind-treatment-hairy-cell-leukemia" target="">Press Release</a><br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="f94e6c68-1eca-4629-a6c3-399c479e6e7b" href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-lumoxiti" title="Drug Trials Snapshots: LUMOXITI">Drug Trials Snapshot</a></td>
		</tr><tr><td>35.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210806 ">Pifeltro</a></span></span></span></span></td>
			<td>doravirine</td>
			<td style="width: 100.2px;">8/30/2018</td>
			<td style="width: 907.79px;">To treat HIV-1 infection in adult patients<br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-pifeltro" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>34.</td>
			<td><span><span><span><span><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=211109 ">Xerava</a></span></span></span></span></span></span></span></span></span></span></span></span></td>
			<td>eravacycline</td>
			<td style="width: 100.2px;">8/27/2018</td>
			<td style="width: 907.79px;">To&nbsp;treat complicated intra-abdominal infections in patients 18 years of age and older<br><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="925c3d6d-5d9b-464b-a003-74e9b6daeaa6" href="/drugs/drug-approvals-and-databases/drug-trial-snapshot-xerava" title="Drug Trial Snapshot: XERAVA">Drug Trials Snapshot</a></td>
		</tr><tr><td>33.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761090 ">Takhzyro</a></span></span></span></span></td>
			<td>lanadelumab</td>
			<td style="width: 100.2px;">8/23/2018</td>
			<td style="width: 907.79px;">To treat types I and II hereditary angioedema<br><a href="/drugs/drug-safety-and-availability/fda-approves-new-treatment-rare-hereditary-disease" target="">More Information</a><br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-takhzyro" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>32.</td>
			<td><span><span><span><span>O<a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761094 ">xervate</a></span></span></span></span></td>
			<td>cenegermin-bkbj</td>
			<td style="width: 100.2px;">8/22/2018</td>
			<td style="width: 907.79px;">To treat neurotrophic keratitis<br><a href="/news-events/press-announcements/fda-approves-first-drug-neurotrophic-keratitis-rare-eye-disease" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-oxervate" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>31.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=206709">Diacomit</a></span></span></span></span></td>
			<td>stiripentol</td>
			<td style="width: 100.2px;">8/20/2018</td>
			<td style="width: 907.79px;">To treat seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam<br><a href="/drugs/drug-approvals-and-databases/drug-trial-snapshot-diacomit" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>30.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=208623 ">Galafold</a></span></span></span></span></td>
			<td>migalastat</td>
			<td style="width: 100.2px;">8/10/2018</td>
			<td style="width: 907.79px;">To treat treat adults with Fabry disease.<br><a href="/news-events/press-announcements/fda-approves-new-treatment-rare-genetic-disorder-fabry-disease" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-galafold" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>29.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=209627 ">Annovera</a></span></span></span></span></td>
			<td>segesterone acetate and ethinyl estradiol vaginal system</td>
			<td style="width: 100.2px;">8/10/2018</td>
			<td style="width: 907.79px;">New vaginal ring used to prevent pregnancy for&nbsp;an entire&nbsp;year<br><a href="/news-events/press-announcements/fda-approves-new-vaginal-ring-one-year-birth-control" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trial-snapshot-annovera" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>28.</td>
			<td><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210922">Onpattro</a></span></span></span></span></span></span></span></span></td>
			<td>patisiran</td>
			<td style="width: 100.2px;">8/10/2018</td>
			<td style="width: 907.79px;">To treat&nbsp;the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adult patients<br><a href="/news-events/press-announcements/fda-approves-first-its-kind-targeted-rna-based-therapy-treat-rare-disease" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trial-snapshot-onpattro" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>27.</td>
			<td><span><span><span><span><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761051">Poteligeo</a></span></span></span></span></span></span></span></span></td>
			<td>mogamulizumab-kpkc</td>
			<td style="width: 100.2px;">8/8/2018</td>
			<td style="width: 907.79px;">To treat two rare types of non-Hodgkin lymphoma<br><a href="/news-events/press-announcements/fda-approves-treatment-two-rare-types-non-hodgkin-lymphoma" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-poteligeo" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>26.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210923 ">Mulpleta</a></span></span></span></span></td>
			<td>lusutrombopag</td>
			<td style="width: 100.2px;">7/31/2018</td>
			<td style="width: 907.79px;">To treat thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure<br><a href="/drugs/drug-approvals-and-databases/drug-trial-snapshot-mulpleta" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>25.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210589 ">Omegaven</a></span></span></span></span></td>
			<td>fish oil triglycerides</td>
			<td style="width: 100.2px;">7/27/2018</td>
			<td style="width: 907.79px;">As a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis<br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-omegaven" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>24.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210450 ">Orilissa</a></span></span></span></span></td>
			<td>elagolix sodium</td>
			<td style="width: 100.2px;">7/23/2018</td>
			<td style="width: 907.79px;">For the management of moderate to severe pain associated with endometriosis<br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-orilissa" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>23.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210795 ">Krintafel</a></span></span></span></span></td>
			<td><span span="">tafenoquine</span></td>
			<td style="width: 100.2px;">7/20/2018</td>
			<td style="width: 907.79px;">For the radical cure (prevention of relapse) of Plasmodium vivax malaria<br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-krintafel" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>22.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=211192">Tibsovo</a></span></span></span></span></td>
			<td>ivosidenib</td>
			<td style="width: 100.2px;">7/20/2018</td>
			<td style="width: 907.79px;">To treat patients with relapsed or refractory acute myeloid leukemia<br><a href="/news-events/press-announcements/fda-approves-first-targeted-treatment-patients-relapsed-or-refractory-acute-myeloid-leukemia-who" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-tibsovo" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>21.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=208627 ">TPOXX</a></span></span></span></span></td>
			<td>tecovirimat</td>
			<td style="width: 100.2px;">7/13/2018</td>
			<td style="width: 907.79px;">To treat smallpox<br><a href="/news-events/press-announcements/fda-approves-first-drug-indication-treatment-smallpox" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trial-snapshot-tpoxx" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>20.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210496">Braftovi</a></span></span></span></span></td>
			<td>encorafenib</td>
			<td style="width: 100.2px;">6/27/2018</td>
			<td style="width: 907.79px;">To treat unresectable or metastatic melanoma<br><a href="/drugs/approved-drugs/fda-approves-encorafenib-and-binimetinib-combination-unresectable-or-metastatic-melanoma-braf" target="">FDA Announcement</a><br><a href="/drugs/drug-approvals-and-databases/drug-trial-snapshot-braftovi" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>19.</td>
			<td><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210498 ">Mektovi</a></td>
			<td>binimetinib</td>
			<td style="width: 100.2px;">6/27/2018</td>
			<td style="width: 907.79px;">To treat unresectable or metastatic melanoma<br><a href="/drugs/approved-drugs/fda-approves-encorafenib-and-binimetinib-combination-unresectable-or-metastatic-melanoma-braf" target="">FDA Announcement</a><br><a href="/drugs/drug-approvals-and-databases/drug-trial-snapshot-mektovi" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>18.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210303 ">Zemdri</a></span></span></span></span></td>
			<td>plazomicin</td>
			<td style="width: 100.2px;">6/25/2018</td>
			<td style="width: 907.79px;">To treat adults with complicated urinary tract infections<br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshot-zemdri" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>17.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210365">Epidioloex</a></span></span></span></span></td>
			<td>cannabidiol</td>
			<td style="width: 100.2px;">6/25/2018</td>
			<td style="width: 907.79px;">To treat rare, severe forms of epilepsy<br><a href="/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-epidiolex" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>16.</td>
			<td><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;applno=210867">Moxidectin</a></td>
			<td>moxidectin</td>
			<td style="width: 100.2px;">6/13/2018</td>
			<td style="width: 907.79px;">To treat onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older<br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-moxidectin" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>15.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=207924 ">Olumiant</a></span></span></span></span></td>
			<td>baricitinib</td>
			<td style="width: 100.2px;">5/31/2018</td>
			<td style="width: 907.79px;">To treat moderately to severely active rheumatoid arthritis<br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-olumiant" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>14.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761079 ">Palynziq</a></span></span></span></span></td>
			<td>pegvaliase-pqpz</td>
			<td style="width: 100.2px;">5/24/2018</td>
			<td style="width: 907.79px;">To treat&nbsp;adults with a rare and serious genetic disease known as phenylketonuria (PKU)<br><a href="/news-events/press-announcements/fda-approves-new-treatment-pku-rare-and-serious-genetic-disease" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trial-snapshot-palynziq" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>13.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210238 ">Doptelet</a></span></span></span></span></td>
			<td>avatrombopag</td>
			<td style="width: 100.2px;">5/21/2018</td>
			<td style="width: 907.79px;">To treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure<br><a href="/news-events/press-announcements/fda-approves-new-drug-patients-chronic-liver-disease-who-have-low-blood-platelets-and-are-undergoing" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trial-snapshot-doptelet" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>12.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=207078 ">Lokelma</a></span></span></span></span></td>
			<td>sodium zirconium cyclosilicate</td>
			<td style="width: 100.2px;">5/18/2018</td>
			<td style="width: 907.79px;">To treat&nbsp;hyperkalemia<br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-lokelma" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>11.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761077 ">Aimovig</a></span></span></span></span></td>
			<td>erenumab-aooe</td>
			<td style="width: 100.2px;">5/17/2018</td>
			<td style="width: 907.79px;">For the preventive treatment for migraine<br><a href="/news-events/press-announcements/fda-approves-novel-preventive-treatment-migraine" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-aimovig" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>10.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=209229 ">Lucemyra</a></span></span></span></span></td>
			<td>lofexidine hydrochloride</td>
			<td style="width: 100.2px;">5/16/2018</td>
			<td style="width: 907.79px;">For the non-opioid treatment for management of opioid withdrawal symptoms in adults<br><a href="/news-events/press-announcements/fda-approves-first-non-opioid-treatment-management-opioid-withdrawal-symptoms-adults" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-lucemyra" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>9.</td>
			<td><span><span><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210493 ">Akynzeo</a></span></span></span></span></td>
			<td>fosnetupitant and palonosetron</td>
			<td style="width: 100.2px;">4/19/2018</td>
			<td style="width: 907.79px;">To prevent acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy<br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-akynzeo" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>8.</td>
			<td><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761068">Crysvita</a></span></span></td>
			<td>burosumab-twza</td>
			<td style="width: 100.2px;">4/17/2018</td>
			<td style="width: 907.79px;">To treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets<br><a href="/news-events/press-announcements/fda-approves-first-therapy-rare-inherited-form-rickets-x-linked-hypophosphatemia" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-crysvita" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>7.</td>
			<td><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=209299">Tavalisse</a></span></span></td>
			<td>fostamatinib</td>
			<td style="width: 100.2px;">4/17/2018</td>
			<td style="width: 907.79px;">To treat thrombocytopenia in adult patients with persistent or chronic immune thrombocytopenia (ITP)<br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshot-tavalisse" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>6.</td>
			<td><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761067">Ilumya</a></span></span></td>
			<td>tildrakizumab</td>
			<td style="width: 100.2px;">3/20/2018</td>
			<td style="width: 907.79px;">To treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy<br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-ilumya" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>5.</td>
			<td><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761065 ">Trogarzo</a></span></span></td>
			<td>ibalizumab-uiyk</td>
			<td style="width: 100.2px;">3/6/2018</td>
			<td style="width: 907.79px;">To treat HIV patients who have limited treatment options<br><a href="/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-who-have-limited-treatment-options" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-trogarzo" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>4.</td>
			<td><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210951">Erleada</a></span></span></td>
			<td>apalutamide</td>
			<td style="width: 100.2px;">2/14/2018</td>
			<td style="width: 907.79px;">To treat a certain type of prostate cancer using novel clinical trial endpoint<br><a href="/news-events/press-announcements/fda-approves-new-treatment-certain-type-prostate-cancer-using-novel-clinical-trial-endpoint" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trial-snapshot-erleada" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>3.</td>
			<td><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210491">Symdeko</a></span></span></td>
			<td>tezacaftor; ivacaftor</td>
			<td style="width: 100.2px;">2/12/2018</td>
			<td style="width: 907.79px;">To treat cystic fibrosis in patients age 12 years and older<br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-symdeko" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>2.</td>
			<td><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210251">Biktarvy</a></span></span></td>
			<td>bictegravir, embitcitabine, tenofovir alafenamide</td>
			<td style="width: 100.2px;">2/7/2018</td>
			<td style="width: 907.79px;">To treat infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen<br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshot-biktarvy" target="">Drug Trials Snapshot</a></td>
		</tr><tr><td>1.</td>
			<td><span><span><a href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=208700">Lutathera</a></span></span></td>
			<td>lutetium Lu 177 dotatate</td>
			<td style="width: 100.2px;">1/26/2018</td>
			<td style="width: 907.79px;">To treat a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs).<br><a href="/news-events/press-announcements/fda-approves-new-treatment-certain-digestive-tract-cancers" target="">Press Release</a><br><a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots-lutathera" target="">Drug Trials Snapshot</a></td>
		</tr></tbody>
